Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript

SA Transcripts 161.58K Followers Follow Immunovant, Inc. ( IMVT ) Q1 2027 Earnings Call August 6, 2026 8:00 AM EDT Company Participants Conference Call Participants Stephanie Lee Griffin - Roivant Sciences Ltd. Matthew Gline - Roivant Sciences Ltd. Lut Ming Cheng - JPMorgan Chase & Co, Research Division David Risinger - Leerink Partners LLC, Research Division Samantha Lynn Semenkow - Citigroup Inc. Exchange Research Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Andy Chen Yatin Suneja - Guggenheim Securities, LLC, Research Division Yaron Werber - TD Cowen, Research Division Thomas Smith - Leerink Partners LLC, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Samuel Slutsky - LifeSci Capital, LLC, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to Roivant's First Quarter 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today's call is being recorded. I would now like to hand the conference over to your first speaker today, Stephanie Lee. Thank you. Please go ahead. Stephanie Lee Griffin Roivant Sciences Ltd. Good morning, and thanks for joining today's call to review Roivant's financial results for the first quarter ended June 30, 2026. I'm Stephanie Lee with Roivant. Presenting today, we have Matt Gline, CEO of Roivant. For those dialing in via conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at www.investor.roivant.com. We'll also be providing the current slide numbers as we present to help you follow along. I'd like to remind you that we'll be making certain forward-looking statements during today's presentation. We strongly encourage you to review the information that we have filed with the SEC for more information regarding these forward-looking statements and related risks and uncertainties. And with that, I'll turn it over to Matt. Matthew Gline